Yu Aoh, Tsung-Wei Hou, Cheng-Chia Yang, Ching-Mao Chang, Shih-Pin Chen, I-Ju Tsai, Chin-Wen Cheng, Chun-Pai Yang
Chronic migraine (CM) is a profoundly debilitating condition that has detrimental clinical and social outcomes. Over the past two decades, novel small-molecule calcitonin gene related peptide (CGRP) receptor antagonists, known as gepants, and CGRP monoclonal antibodies (mAbs) have been developed, ushering in a new era of migraine-specific treatment. In this review, we discuss the literature investigating the role of gepants for the treatment of CM. Numerous completed and ongoing clinical studies have conclusively demonstrated the safety, tolerability, and efficacy of several gepants for the acute treatment of migraine...
February 13, 2024: Journal of the Chinese Medical Association: JCMA